Pathstone Family Office’s Outset Medical OM Stock Holding History

Pathstone Family Office’s Portfolio OM Stock Details OM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-33	Closed	-$28K	–	1143
2020 Q4	$28K	Buy	+33	New	+$25.4K	﹤0.01%	625

Other funds holding OM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DCP

D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Family Office's OM Position: Q1 2021 in Review

Pathstone Family Office sold out of Outset Medical (OM) in Q1 2021, closing a stake of 33 shares — an estimated $28K sold.

Pathstone Family Office first reported a position in OM in Q4 2020 and held it in 1 quarter. The position peaked at $28K in Q4 2020. 111 funds tracked by Wall St. Rank hold OM as of Q1 2021.

Pathstone Family Office reported no remaining Outset Medical position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 33 Outset Medical shares in Q1 2021, an estimated $28K.
Pathstone Family Office first reported a position in Outset Medical in Q4 2020 and held it in 1 quarter.
Pathstone Family Office's Outset Medical position peaked at $28K in Q4 2020.
111 funds tracked by Wall St. Rank held Outset Medical as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.